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Abstract CD1d-deficient (CD1d3=3) mouse lymphocytes were
analyzed to classify the natural killer T (NKT) cells without
reactivity to CD1d. The cells bearing a VK19.1^JK26 (AV19^
AJ33) invariant TCR K chain, originally found in the peripheral
blood lymphocytes, were demonstrated to be abundant in the
NK1.1 but not NK1.13 T cell population isolated from
CD1d3=3 mice. Moreover, more than half (11/21) of the hybrid
cell lines established from CD1d3=3 NKT cells expressed the
VK19.1^JK26 invariant TCR K chain. The expression of the
invariant VK19.1^JK26 mRNA was absent in L2-microglobulin-
deficient mice. Collectively, the present findings suggest the
presence of a second NKT cell repertoire characterized by an
invariant TCR K chain (VK19.1^JK26) that is selected by an
MHC class I-like molecule other than CD1d. ß 2002 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Natural killer T (NKT) cells are de¢ned as lymphocytes
bearing both the common NK marker NK1.1, a member of
the NKR-P1 gene family, and TCR^CD3 complex [1,2]. The
TCR repertoire of the majority of NKT cells consists of an
invariant VK14-JK281 chain [3,4] paired preferentially with a
polyclonal VL8, VL7 and VL2 [3,5,6]. This highly skewed
TCR KL repertoire is positively selected by the non-polymor-
phic MHC class I-like CD1d molecule in association with L2-
microglobulin (L2m) [7^11], and is shown to be reactive to
certain glycolipids in the context of CD1d [12,13]. The CD4/
CD8 coreceptor phenotype of this major NKT cell repertoire
is CD4 or CD43CD83 double negative (DN) [7,8]. An im-
portant feature of NKT cells is their ability to secrete both
pro-in£ammatory (Th1) cytokines such as interferon (IFN)-Q
and anti-in£ammatory (Th2) cytokines such as interleukin
(IL)-4 and IL-10 upon stimulation through the semi-invariant
TCR [14^17], suggesting their pivotal roles in immuno-regu-
latory functions including tumor immunity [18,19].
Recent studies revealed that NKT cells are heterogeneous in
terms of TCR structure, CD1d-reactivity, and CD4/CD8 co-
receptor expression although the VK14^JK281, CD1d-re-
stricted, CD4 or DN NKT cell repertoire (Va14 NKT cell)
is most abundant [20^23]. For instance, CD1-independent
CD8 NKT cells are relatively common in spleen and bone
marrow. Classi¢cation of NKT cell subsets is necessary for
understanding the immuno-regulatory functions of NKT cells,
but such attempts have just started and further investigations
are required.
In the current study, we demonstrate the presence of a
novel NKT cell repertoire (designated as VK19 NKT cell)
characterized by the expression of a VK19.1^JK26 (AV19^
AJ33) invariant TCR K chain that was ¢rst found in human,
bovine, and a transporter associated with antigen processing
(Tap)-1-de¢cient mouse peripheral blood by PCR techniques
[24].
2. Materials and methods
2.1. Mice
C57BL/6 mice were purchased from Sankyo Service Co. (Tokyo,
Japan). CD1d3=3 (BALB/c U 129SV F2) mice were obtained from
Dr. M.J. Grusby [9]. They were backcrossed to C57BL/6 mice for
several generations and CDld3=3, H-2b, NK1.1 mice were selected
and used. L2m3=3 mice (C57BL/6 background) were obtained from
Jackson Laboratory (Bar Harbor, ME, USA).
2.2. Cell preparation
Single cell suspensions were prepared from the liver, spleen, bone
marrow, and thymus. Total liver cells were resuspended in a 40%
isotonic Percoll solution (Pharmacia, Uppsala, Sweden), and under-
laid with an 80% Percoll solution. Mononuclear cells were isolated
from the 40^80% interface after centrifugation for 20 min at 900Ug.
Spleen, and bone marrow (femur, tibia) mononuclear cells were en-
riched by density gradient centrifugation using Lymphosepar II
(d = 1.090, IBL, Gunma, Japan).
2.3. Flow cytometry and antibodies
Cells were pretreated with rat IgG2b mAb, 2.4 G2 (anti-FcQR II,
III), to saturate FcR binding. Speci¢c staining was then performed
with a combination of the following conjugated mAbs: H57-597 (anti-
TCR L)PE, PK136 (anti-NK1.1)biotin, GK1.5 (anti-CD4)PE, 53-6.7
(anti-CD8)PE, B20.6 (anti-VL2)FITC, KJ25 (anti-VL3)FITC, KT4 (anti-
VL4)FITC, MR9-4 (anti-VL5.1, 5.2)FITC, RR4-7 (anti-VL6)FITC, TR310
(anti-VL7)FITC, F23.1 (anti-VL8)FITC, MR10-2 (anti-VL9)FITC, B21.5
(anti-VL10)FITC, RR3-15 (anti-VL11)FITC, MR11-1 (anti-VL12)FITC,
MR12-3 (anti-VL13)FITC, and 14-2 (anti-VL14)FITC. Biotinylated
mAbs were revealed with streptavidin-FITC or PE. The stained cells
were analyzed on a FACScan £ow cytometer equipped with the Cell
Quest software (Becton Dickinson, San Jose, CA, USA).
2.4. Preparation of NKT cell hybridomas
NKT cell hybridomas were produced by fusing NK1.1 T cells with
0014-5793 / 02 / $22.00 ß 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 2 5 0 9 - 7
*Corresponding author. Fax: (81)-42-724 6317.
E-mail address: michio@libra.ls.m-kagaku.co.jp (M. Shimamura).
Abbreviations: NKT, natural killer T; L2m, L2-microglobulin; DN,
CD43CD83 double negative; Tap, transporter associated with anti-
gen processing; RACE, rapid ampli¢cation of cDNA ends; DIG, di-
goxigenin; HPRT, hypoxanthine phosphoribosyltransferase
FEBS 25930 8-4-02
FEBS 25930 FEBS Letters 516 (2002) 97^100
the TCR K3L3 variant of the BW5147 thymoma [25] essentially as
described previously [26]. Brie£y, NK1.1 TCR KL cells were sorted
from liver lymphocytes of CD1d3=3 mice on a FACStar (Becton
Dickinson). Their purity for several sortings was more than 95%.
They were cultured with anti-TCR CL mAb (H57-597, 1 Wg/ml),
and rIL-7 (20 ng/ml, Pharmingen, San Diego, CA, USA) in the pres-
ence of irradiated (2000R) spleen cells. rIL-2 (25 U/ml) was added
after 2 days. On day 4, the recovered cells were fused with BW5147
K3L3 by the standard technique. Growing hybridomas were screened
for expression of TCR KL by £ow cytometry and positive wells were
subcloned by limiting dilution.
2.5. RT-PCR
Total RNA was extracted from mouse tissues. It was digested with
DNase I, extracted with phenol, and precipitated with ethanol. Then,
cDNA was prepared from total RNA using RT-PCR kits (Takara,
Tokyo, Japan). RT-PCRs were performed using the following prim-
ers: (5PVK19.1) 5P-GCTTCTGACAGAGCTCCAG-3P ; (3PJK26)5P-
CTTGGTCCCAGAGCCCC-3P ; (5PCK) 5P-GAACCCAGAACC-
TGCTGTGT-3P ; (3PCK) 5P-TGGCGTTGGTCTCTTTTGAAG-3P ;
(5P-hypoxanthine phosphoribosyltransferase (HPRT)) 5P-GTTGGA-
TACAGGCCAGACTTTGTTG-3P ; (3P-HPRT) 5P-GAGGGTAGG-
CTGGCCTATAGGCT-3P. The RT-PCR products obtained with
the 5PVK19.1 and 3PJK26 primers were analyzed by Southern blot
using a digoxigenin (DIG)-labeled probe. A probe was prepared
from the PCR products obtained with these primers (5P PstI/3PEcoRI
digest, 360 bp), and labeled using a DIG High Prime DNA labeling
kit (Roche, Switzerland).
2.6. 5P RACE (rapid ampli¢cation of cDNA ends) analysis
RACE was performed on cDNAs prepared from the CD1d3=3 liver
NKT cell hybridomas using a 5P-full RACE core set (Takara, Japan).
A 5P-end phosphorylated reverse Caprimer (5P-ATCTTGGCAGGT-
3P) was used as a reverse transcription primer. After circulization of
the cDNA, the following pairs of primers were used for the ¢rst and
the second PCR. First PCR: 5P-AAGTCGGTGAACAGGCAGAG-
3P, 5P-GACCTTGCAAGTAGTGACTG-3P. Second PCR: 5P-CTGG-
TACACAGCAGGTTCTG-3P, 5P-CGATACCTAAGGTTCTCGTT-
3P.
2.7. DNA sequencing
The PCR products were cloned into the pCRII vector (Invitrogen,
USA). DNA sequencing was performed using sequencing kits (Amer-
sham Life Science, USA), a sequencing primer (FITC-labeled oligo-
nucleotide complementary to T7 and/or Sp6 promoter) and a DNA
sequencer (Model 3000, Hitachi, Japan).
3. Results
3.1. VK19.1^JK26 invariant K-bearing cells as one of the major
components of NKT cells in CD1d3=3 mice
Analysis of NK1.1 TCR KL cells in CD1d3=3 and
L2m3=3 mice revealed that NKT cell repertoires other than
the major CD1d-dependent repertoire with the VK14^JK281
invariant K chain (VK14 NKT cell) are present ([27] ; M. Shi-
mamura, unpublished results). The expression of CD4/CD8
coreceptors by the residual NKT cells in CD1d3=3 ([20,27],
data not shown) and JK2813=3 [21] mice was strongly skewed
to CD8. These ¢ndings also support the existence of NKT
cells other than VK14 NKT cells.
Hybrid cell lines were produced from CD1d3=3 liver NKT
cells by fusion with thymoma, BW5147, to characterize fur-
ther the NKT cell repertoires. The TCR VK and VL usage of
the hybrid lines thus established were determined by cDNA
sequencing and FACS analysis, and are summarized in Table
1. Astonishingly, more than half of the hybrid lines expressed
TCR K chain with rearrangement between VK19.1 (AV19)
and JK26 (AJ33), which was originally found as the second
invariant TCR K chain in human, bovine and murine periph-
eral blood by PCR technology [24].
The VK19.1^JK26 junctional sequences of these hybrid lines
are shown in Fig. 1. A few nucleotide conversions from the
germ-line sequence were observed in some cell lines. However,
they were limited to those causing only one amino acid alter-
Table 1
VK and VL usage of the hybrid lines derived from NKT cells iso-
lated from CD1-de¢cient mice
Cell line VK19.1^JK26a VL
NB102 ^ 2
NB103 + 2
NB104 ^ ?b
NB110 ^ 4
NB115 + ?b
NB116 + 6
NB201 + 7
NB202 + 6
NB204 + 8
NB206 + 4
NB208 ^ 8
NB209 ^ 6
NB211 ^ 8
NB212 + 5
NB213 + 8
NB215 + 6
NB308 ^ 8
NB403 + 8
NB404 ^ 6
NB405 ^ 8
NB408 ^ 8
aVK usage of the cell lines was determined by the cDNA sequencing
(11/21 showed expression).
bVL other than VL 2^14.
Fig. 1. VK19.1^JK26 junctional sequences of the hybrid lines pro-
duced from CD1d3=3 NKT cells. The sequences were obtained
from analysis of the 5P RACE and/or RT-PCR products. The 3P-
end VK19.1 and the 5P-end JK26 germ-line sequences are shown as
references. The ‘canonical sequence’ produced from the VK19.1 and
JK26 germ-line sequences without any modi¢cations is shown as the
sequence for NB103. Changes relative to it are shown in some cell
lines.
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ation in the junction, thus, the VK19.1^JK26 junctional se-
quences are quite homogeneous similar to the VK14^JK281
invariant TCR K chain [28]. These ¢ndings indicate that an
NKT cell repertoire bearing an invariant VK19.1^JK26 recep-
tor (VK19 NKT cell) is present as a major component of NKT
cells in CD1d3=3 mice.
Next, attempts were made to determine whether the invar-
iant VK19.1^JK26 K chain is expressed mainly by VK19 NKT
cells or also used by conventional T cells. Both NK1.1 TCR
KL and NK1.13 TCR KL cells were enriched from
CD1d3=3 livers and the junctional sequences between
VK19.1 and CK in both fractions were analyzed (Table 2).
The ratio of invariant VK19.1^JK26 sequences to total
VK19.1 sequences obtained from the NK1.1 fraction was
63% on the average of the independent experiments, whereas
the ratio from NK1.13 fraction was 8%, thus indicating that
the invariant VK19.1^JK26 chain is predominantly used by
VK19 NKT cells.
3.2. VL usage of the Va19 hybridomas
VL usage of the VK19 NKT cell lines obtained from
CD1d3=3 liver was found to be skewed to VL8 (3/11) and
VL6 (3/11) (Table 1). Furthermore, the VK19.1^JK26 junction-
al sequences of VL8 VK19 NKT cell lines were those made
from the intact germ-line sequence, but in contrast, the se-
quences of VL6 VK19 NKT cell lines were subjected to junc-
tional modi¢cation, thus suggesting the preferential combina-
tion of the invariant VK19.1^JK26 K chain with a certain
L chain depending on the micro-heterogeneity of the K chain.
As a result, most Va19 NKT cells seem to express a quite
homogeneous TCR KL heterodimer.
3.3. Tissue distribution of the expression of the invariant
VK19.1^JK26 mRNA
The expression of the invariant VK19.1^JK26 mRNA was
analyzed by RT-PCR in the lymphoid organs to examine
tissue distribution of VK19 NKT cells. The invariant
VK19.1^JK26 mRNA was produced more or less in all the
organs examined, but the expression was markedly enhanced
in the adult bone marrow of normal mice (Fig. 2A). The
mRNA was found in the CD1d3=3 as well as normal bone
marrow, but not in the L2m3=3 mice (Fig. 2B). Collectively, it
is suggested that VK19 NKT cells are abundant in bone mar-
row and that they are positively selected by L2m-associated
MHC class I-like molecules other than CD1d.
4. Discussion
The presence of a new NKT cell bearing an invariant
VK19.1^JK26 K chain is demonstrated. Next to the VK14
NKT cell, the VK19 NKT cell is the second NKT cell subset
characterized by a strictly distinct TCR repertoire.
It has been revealed by quantitative PCR analyses that cells
bearing mRNA of the human counterpart of the murine in-
variant VK19.1^JK26 (human VK7.2^JK33) account for 0.1^
0.2% of peripheral blood lymphocytes [24]. If the tissue dis-
tribution of the invariant K chain-bearing cells in human is
common to other species, the newly identi¢ed NKT cell subset
may not be a minor cell component. Establishment of speci¢c
antibodies against the invariant TCR K chain is required to
exactly determine their frequency in vivo by FACS analysis.
The CD4/CD8 coreceptor phenotype of the VK19 NKT cell
lines, which represent more than half of the NKT cell hybrid-
omas examined here (Table 1), was DN; only NB213 ex-
pressed low levels of CD4 (data not shown). This phenotype
does not re£ect the phenotype of the NKT cells in CD1d3=3
mouse livers where the ratio of CD4, DN and CD8 NKT
cells in CD1d3=3 mouse livers was about 1:2:3 ([20]; data not
shown). In contrast, the CD4/CD8 phenotype of a panel of
thymic VK14 NKT cell hybrid lines [28] produced by the same
protocols used in this study (CD4, 60%; DN, 40%; M. Shi-
mamura, unpublished results) well corresponds to the pheno-
type of the intact thymic NKT cells [20^22]. Thus, one possi-
ble interpretation of these ¢ndings is that VK19 NKT cell lines
chie£y represent both the DN and CD8 but not CD4 NKT
cell subsets and that the VK19 NKT cell lines derived from the
CD8 subset might lose the CD8 expression during the estab-
lishment of the cell lines.
Table 2
Abdundance of the invariant TCR VK19.1^JK26 receptor-bearing
cells in the NK.1.1 cell fraction among CD13=3 liver lymphocytes
Invariant VK19.1^JK26/total VK19 sequences
NK1.1 fraction
Experiment 1 3/8
2 11/13
3 5/9
NK1.13 fraction
Experiment 1 1/10
2 1/15
Fig. 2. Expression of the invariant VK19.1^JK26 K chain mRNA de-
termined by RT-PCR analyses. A: Distribution in normal mouse
lymphoid tissues. The expression of the VK19^JK26 mRNA was
normalized by the expression of the TCR K constant region mRNA
to estimate the proportion of VK19 NKT cells to total T cells. B:
The expression of VK19.1^JK26 mRNA in normal, CD1d3=3, and
L2m3=3 bone marrow. The expression of HPRT mRNA is shown
as a reference. cDNA prepared from 1, 1/3, or 1/9 Wg total RNA
was used as template.
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Development of VK19 NKT cells is dependent on L2m-as-
sociated MHC class I-like molecules other than CD1d. Judg-
ing from the expression of the invariant VK19.1^JK26 mRNA
in Tap-13=3 mouse peripheral blood [24], the selection mole-
cule is one of the MHC class Ib molecules. Joyce et al. sug-
gested the presence of TL (H-2T18d)-dependent NKT cells
[29]. However, VK19 NKT cell hybridomas were not respon-
sive to H-2T3b (homologous to H-2T18d)-transfectants in vi-
tro (data not shown). Thus, it is likely that VK19 NKT cells
are restricted by an MHC class Ib molecule other than TL
antigens.
The speci¢c antigens recognized by VK19 NKT cells have
not been identi¢ed. The stringent requirement of the TCR K
chain structure (Fig. 2) combined with the preferential usage
of certain VLs (Table 1) suggests the formation of semi-invar-
iant TCR KL receptors in VK19 NKT cells. Taking into ac-
count the Tap-independency for antigen processing, the spe-
ci¢c antigens for VK19 NKT cells are assumed to be certain
limited substances other than peptides, as similar to the spe-
ci¢c antigens for VK14 NKT cells such as K-GalCer [12].
A panel of VK19 NKT cell hybridomas apparently exhib-
ited Th2-type pro¢les of cytokine secretion following TCR^
CD3 complex stimulation (data not shown). Thus, it is possi-
ble that VK19 NKT cells keep a certain content in the NKT
cell population and share immune-regulatory roles with VK14
NKT cells under the control of MHC class Ib molecules other
than CD1d. Determination of the MHC restriction for this
new NKT cell repertoire is required to understand their spe-
ci¢c roles in the immune system.
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